适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864CTIS2023-506541-39-00Amgen Inc.377
招募中
1 期
Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate CancerCTIS2023-504361-23-00Amgen Inc.461
招募中
1 期
Prospective head-to-head comparison of cardiac [18F]-MFBG PET versus [123I]-MIBG SPECT in the differentiation between Parkinson’s disease and multiple system atrophy and between dementia with Lewy bodies and Alzheimer’s disease.Parkinson's disease, Alzheimer's Disease, Multiple systems atrophy - parkinsonian variant, Dementia with Lewy BodiesCTIS2023-506508-18-00Z Leuven113
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteersdiabetes mellitushypertensionCTIS2024-511526-31-00Celon Pharma S.A.38
进行中（未招募）
1 期
A phase 2 evaluation for patients who undego kidney transplant requires long term theraphy that suppress immune response to prevent damage rejection by stopping the immune system from attacking the healthy tissues in the body.EUCTR2013-002090-21-ATBristol-Myers Squibb International Corporation240